Earnings call transcript: Piramal Finance posts 67% profit jump in Q2 2027

Piramal Finance's Q2 FY 2027 net profit rose 67% year on year to INR 545 crores, while total income increased 33% to INR 1,767 crores and pre-provisioning operating profit grew 64% to INR 846 crores. AUM rose 24% to INR 113,112 crores, asset quality remained stable, and incremental long-term borrowing costs declined to 8.46%; management reiterated FY 2027 targets of 25% AUM growth and 50% profit growth. The company flagged a possible 18–24 bps gross FY 2028 ROA impact from proposed insurance commission rules, while shares were nearly unchanged, down 0.08%.

Analysis

The earnings quality is better than headline PAT growth alone suggests: operating leverage and lower funding costs are supporting the growth franchise, but reported profit also received a legacy-book recovery benefit. As the legacy portfolio approaches immateriality, that runoff tailwind—and the associated NIM convergence—will fade; the next leg must come from sustainable expense reduction and asset mix, not balance-sheet cleanup. That mix shift is not free: more unsecured and gold lending can lift yields while increasing loss volatility, particularly if small-ticket or borrower-level gold-loan stress broadens. Management’s underwriting discipline is a claim to verify against vintages and delinquencies, not a substitute for through-cycle evidence.

Near term, maturing higher-cost debt offers a company-specific offset to tighter rates, but it does not eliminate repricing risk: customer rate pass-through may lag, and the liability advantage depends on refinancing spreads staying below the retiring book’s cost. Over 1–3 months, watch funding spreads, credit costs, and progress toward the Q4 ROAUM target. Over 6–18 months, the draft insurance-commission change is a real hurdle to the profitability bridge; the claimed offset through its insurance stake and expense actions is uncertain until final rules and net economics are disclosed. The capital raise supports growth capacity but also raises the bar for per-share returns. The result alone does not establish a valuation discount or a clean earnings beat. Verify the underlying exchange filing and price data before trading: the supplied headline and quoted share-price presentation appear inconsistent with the earnings text.

Key Decisions for Investors

• No immediate directional trade on this release alone. Treat Piramal Finance as a watchlist long only if subsequent quarters confirm growth-business ROAUM improvement without deterioration in early delinquencies or credit costs; the thesis is falsified by a sustained rise in those measures or a miss to the Q4 ROAUM trajectory.
• Track refinancing economics monthly/quarterly: compare actual all-in borrowing cost and spreads on new issuance with the cost of maturing debt. Reduce the bullish funding-cost thesis if spreads widen enough to erase the refinancing advantage or reported NIM compresses despite legacy runoff.
• Keep exposure to the FY28 earnings bridge conditional on the final insurance-commission rule and quantified net impact after the insurance subsidiary offset. A materially adverse final rule, or guidance that pushes the ROAUM path further out, is a catalyst to reassess rather than assume management mitigation.
• Before acting, reconcile the article with the exchange filing and current traded instrument/quotation: the supplied price currency and headline do not cleanly match the earnings discussion. Do not infer a valuation opportunity from the article’s unsupported valuation commentary.